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Summary Tuberculosis (TB) is a major public health problem in complex emergencies. Humanitarian agencies
usually postpone the decision to offer TB treatment and opportunities to treat TB patients are often
missed. This paper looks at the problem of tuberculosis treatment in these emergencies and
questions whether treatment guidelines could be more ﬂexible than international recommendations.
A mathematical model is used to calculate the risks and beneﬁts of different treatment scenarios with
increasing default rates. Model outcomes are compared to a situation without treatment. An economic
analysis further discusses the ﬁndings in a trade-off between the extra costs of treating relapses and
failures and the savings in future treatment costs. In complex emergencies, if a TB programme could
offer 4-month treatment for 75% of its patients, it could still be considered beneﬁcial in terms of public
health. In addition, the proportion of patients following at least 4 months of treatment can be used as an
indicator to help evaluate the public health harm and beneﬁt of the TB programme.
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Introduction
Measuring the effect of war on the incidence of tuber-
culosis is fraught with methodological problems and the
scarce information available is difﬁcult to interpret. For
instance, the doubling of the incidence of tuberculosis (TB)
from 50 to 109/100 000 observed in the post-war period in
Vietnam (1975–1982) was explained by better case detec-
tion systems rather than an increase in transmission
(Shimao 1986; Barr & Menzies 1994). However, in a
review of the literature in 1994, Barr and Menzies
estimated that the incidence of sputum smear-positive
pulmonary tuberculosis (PTB (+)) was three times higher
among displaced Salvadorians than the national rate in
El Salvador. In England and Wales, notiﬁcations of
tuberculosis increased by 16–19% between 1939 and
1944. A similar increase in the incidence of TB was also
observed in Japan during the Second World War.
The concept complex emergencies characterises
today’s armed conﬂicts and resulting humanitarian disas-
ters. These emergencies represent the ultimate pathway of
state disruption. The complexity refers to the multifaceted
responses by the international community, which are
further complicated by the lack of protection normally
afforded by international treaties, covenants and the
United National Charter during conventional wars (Burkle
1999). The situations in Afghanistan and Somalia are
probably typical examples of such protracted conﬂicts and
never-ending humanitarian disasters. In contrast to natural
disasters, where national governments attempt to provide
emergency assistance to the victims, in complex emergen-
cies they often deny the means to mitigate the effect of
conﬂicts or manipulate the human misery (Buchanan &
Maxwell 1994; Macrae & Zwi 1994). Typically, huma-
nitarian agencies take over from the Ministry of Health the
provision of health care in addition to other relief efforts.
Several small-scale TB programmes have been imple-
mented by humanitarian agencies in complex emergencies,
with varying levels of success. In Southern Sudan in 1997,
nine TB programmes reported a cure rate between 68 and
94.5% among 867 patients (Van Ham, 1998). In Kismayu,
Somalia, Me ´decins Sans Frontie `res (MSF) reported a cure
and completion rate of 80% on 593 patients, from March
1995 to September 1997 (Van Herp, 1998). The African
Medical Research Foundation (AMREF) reported similar
results in South West Somalia from July 1994 through
December 1996 in a cohort of 286 patients (Agutu 1997).
On the other hand, in Liberia a cure rate of 50–60%
forced MSF to stop its involvement in the National TB
Programme in 1994 (Zachariah 1994).
For initiating TB control programmes in complex
emergencies, most agencies follow the international
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unpublished observations; WHO & UNHCR 1997). These
guidelines suggest that TB programmes should focus on
sputum positive pulmonary tuberculosis (PTB (+)) patients
and aim to achieve 85% cure rate with directly observed
treatment (DOT) for 6 months. In this paper, a programme
fulﬁlling these conditions of cure rate and a 6-month
treatment follow-up is deﬁned as optimal.Asub-optimal
programme describes any situation that does not achieve a
85% cure rate and a follow-up of 6 months.
Sincesuchalongtreatmentdurationandhighlevelofcure
rate may not be achievable in many complex emergency
situations, TB programmes are often postponed until pre-
conditions, such as stability and security, are fulﬁlled to
guarantee an optimal programme. However, clinicians face
ethical dilemmas when not offering treatment for tubercu-
losis cases. Programme managers, on the other hand, are
concerned with the instability that characterises complex
emergencies,whichwillincreasetheriskofthedevelopment
of drug resistance, resulting from a sub-optimal TB pro-
gramme. The main barriers encountered and reinforced by
the prevailing insecurity are: (i) the absence of a good
supervised programme, allowing for possible bad manage-
ment (Zachariah 1994); (ii) frequent expatriate staff evac-
uations (Van Ham, 1998; Van Herp, 1998); (iii) sudden
closures of programmes, disruption of supply lines or
displacement of people. Outbursts of violence constitute a
serious threat for the continuity of TB programmes.
Nevertheless, successful programmes have been able to
overcome security and continuity constraints through
imaginative contingencies, such as placing a limited num-
ber of patients on treatment (Van Herp, 1998), run-away
packs with ﬁxed-dose combination drugs, and treatment
cards to help patients get further treatment at a new centre
(Van Ham, 1998). However, in other complex emergencies
like Afghanistan, Angola, Sierra Leone and Burundi, TB
programmes were never started or were postponed for
several years (MSF, personal communications), although
the local security situation had become quiet. In complex
emergencies, many areas remain indeed stable for longer
periods of time. These situations could allow small-scale
treatment opportunities. Meanwhile, private practitioners,
such as drug sellers, medical practitioners and traditional
healers compete with humanitarian agencies in health care
provision. They are likely to offer inadequate TB treatment
under much less supervised circumstances, with little or no
consideration of combined drug therapy and continuity of
treatment and follow up (MSF, personal communications).
This paper provides information that continues to
explore the case of TB control in complex emergencies. To
assist agencies in running TB programmes in such settings,
it investigates the public health risks and beneﬁts of
sub-optimal TB programmes, i.e. programmes with less
than 85% cure rate and where patients follow less than
6 months of treatment. It then considers whether, in a
complex emergency situation, a sub-optimal TB pro-
gramme would be preferable to no TB programme at all.
Methods
Two different perspectives are used to assess the public
health risks and beneﬁts of sub-optimal TB programmes, as
compared to no treatment programme at all. First, a
simpliﬁed mathematical model is constructed to calculate
the health consequences of poor treatment compliance, and
secondly, ﬁndings are discussed further in an economic
analysis which looks at the trade-offs between the extra
costs of treating relapses and failures and the savings in
future treatment costs.
Risk and beneﬁt indicators
The model was created using information from: (i) the
work of Murray et al. (1993) on TB transmission; (ii) from
the same authors (1990) and from WHO (1997) regarding
drug resistance; and (iii) from the work of Vynnycky and
Fine (1998) on TB modelling. The health risks and beneﬁts
of a sub-optimal TB programme for one transmission cycle
were deﬁned by the following outcome indicators:
(i) number of patients cured (conﬁrmed by sputum exam-
ination, not suffering relapse); (ii) number of deaths
averted; (iii) number of new PTB cases averted as a result of
ending TB transmission; (iv) number of cases in which
(single and multiple) drug resistance developed (isolates
from cases of treatment failure or relapse that became
resistant to anti-TB drugs); and (v) number of chronic TB
excreters created (patients who after treatment remain
infectious). To keep the model simple, all treatment failures
and relapses were considered as chronic excreters.
For different treatment durations, risks of treatment
failure (failure to convert to sputum Acid-Fast-Bacilli
(AFB)-negative at the time of discontinuing treatment),
risks of relapse (sputum becoming AFB-positive after
discontinuing treatment within 60 months post-treatment)
and of drug resistance development were estimated or
derived from a variety of studies (East African/BMRC
study 1981; Singapore TB Service/BMRC 1981, 1986,
1988; Hong Kong Chest service/BMRC 1982, 1987;
TB Research Centre of Madras 1983; Baba et al. 1984;
Hong Kong Chest service/TB Research Centre, Madras/
BMRC 1984, 1989; TB Research Centre of Madras and
National TB Institute of Bangalore 1986, 1990; Dutt et al.
1989) (Table 1). The construction of the model indicators
can be found in Table 2.
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When constructing the model, the following assumptions
were made from a variety of papers, which investigate and
discuss the TB transmission and control. Each is referenced
after the assumption created: (i) without TB treatment,
50% of PTB (+) patients will die within 5 years, 25% will
be cured spontaneously and 25% will continue to remain
infectious (Grzybowski & Enarson 1978; Murray et al.
1993; WHO & UNHCR 1997); (ii) there is a 8% risk of
dying while on TB treatment (Murray et al. 1993; Enarson
& Rouillon 1994); (iii) each smear positive TB patient will
infect 12 patients of which 8% will develop clinical TB
(85% of these will be PTB equally distributed between
smear positive and negative cases (Murray et al. 1993;
Dejonghe et al. 1994)); and (iv) patients defaulting less
than 2 months after the onset of treatment are considered
as 100% treatment failures.
The outcome indicators depend on the baseline level of
drug resistance, the type of treatment and the compliance or
treatment duration. Thus, if the baseline single-drug resist-
ance is kept constant at 25% and if all patients are offered
6 months chemotherapy consisting of 2SHRZ/4HR
(2 monthsoftreatmentwithstreptomycin(S),isoniazid(H),
rifampicin (R) and pyrazinamide (Z); followed by 4 months
of treatment with isoniazid and rifampicin), then the above
mentioned indicators can be expressed as a function of the
level of compliance, i.e. the actual duration of drug intake.
Eight different programme scenarios have been construc-
ted, representing each of the 100 patients under treatment.
Each scenario presents varying proportions of patients
adhering to TB treatment for speciﬁc durations. These
scenarios are designed to show a decreasing adherence to
treatment and can be considered therefore as increasingly
sub-optimal. Each outcome indicator was estimated for
each scenario in the following model: Y1 ¼
P
xaya +
xbyb + … + xnyn; where Y1 ¼ probability of outcome y in
scenario1,xatoxnaretheproportionsofpatientscomplying
with treatment for a speciﬁc duration and ya to yn are the
probability of outcome y per treatment duration.
Table 1 Maximal treatment failures (TF), Relapse (Rel) and new single and multi-drug resistance rates obtained from previous studies
Treatment
duration (M)
Drug sensitive population Drug resistant population (i)
TF (%) Rel (%)
New single drug
resistance on (i)
TF (%) Rel (%)
New MDR on (ii)
TF (%) Rel (%) TF (%) Rel (%)
<2 N.A. N.A. 0.0 0.0* N.A. N.A. 2.2 2.2–
21 5 3 2  0.0 0.0 15.0 38.0 2.2 2.2–
3 4 20 0.0 0.4 6.1 23.3 2.2 0.0
4 1 16 0.0 1.0 5.0 20.0 0.0 1.0§
5 1# 8.5 0.0 0.0 4.0 10.0 1.0 0.0
6 1 3.4 0.0 0.0 3.0 5.5 0.7 0.0
M: months; N.A.: not available; (i) resistant to 1 or 2 drugs; (ii) percentages on acquired MDR have been calculated by pooling data
from several studies with similar treatment duration;  based on relapses of smear negative cases;  estimates from drug sensitive popu-
lation;  estimated from outcomes of 3 months treatment; * based on reference of 2 months treatment; – based on reference of 3 months
treatment; § based on PTB ()), culture (+); # based on reference of 4 months treatment.
Table 2 Mathematical model indicator constructions
Total cured ¼ Total number starting treatment (N) – (treatment failures + relapses + deaths while on treatment)
New PTB averted ¼ (total cured – chronic excreters) · number of new infections, created by a TB patient in one year ·
the probability of developing clinical TB · probability of new infection leading to new PTB
Deaths averted ¼ Total cured · probability of dying within 5 years without TB treatment
Single drug resistant PTB ¼ (Total number starting treatment · probability of single drug resistance on treatment failures
and relapses) · number of new infections, created by a TB patient in one year · the probability of developing clinical
TB · probability of new infection leading to new PTB
Multi-drug resistance PTB ¼ (Total number starting treatment · probability of MDR on treatment failures and relapses) · number
of new infections, created by a TB patient in one year · the probability of developing clinical TB · probability of new infection
leading to new PTB
Chronic excreter ¼ All patients failing treatment and all patients relapsing within the ﬁrst 60 months after ending treatment
 The majority of these (80%) dying within the ﬁrst 2 years;  only one transmission cycle studied.
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A simple economic analysis has been used in this paper,
using a public sector perspective, which excludes costs
incurred by the private sector and by private consumers
and collates only those costs incurred by the public sector
in implementing tuberculosis control.
As patients who require re-treatment after failing the
ﬁrst treatment or after relapse need a more expensive and
longer drug regimen, we compared these expected extra
costs per scenario to the savings implied by the number of
new PTB cases averted as a result of ending TB transmis-
sion in the same scenario. The economic implications of
sub-optimal TB programmes were thus looked into
through incremental cost analysis, i.e. the extra cost or gain
per sub-optimal TB programme scenario of 100 treat-
ments, including programme management, laboratory,
drugs, hospitalisation and outpatient care costs, but
assuming that the organisational infrastructure already
exists. This incremental cost analysis based itself on a range
of average marginal costs of TB programmes from three
African countries calculated by Dejonghe et al. (1994).
Results
Health beneﬁts and risks
Table 3 and Figure 1 show the risks and beneﬁt indicators
of sub-optimal TB treatment programmes per 100 or 1000
treatments, as predicted by the mathematical model.
Scenario 0 (the baseline case scenario to which all other
scenarios should be compared) represents 100 PTB (+)
patients, left untreated in a 5-year period, while scenario 1
represents an optimal situation with 100% adherence of all
patients to 6-month treatment. All other scenarios, from 2
to 8, represent increasingly sub-optimal treatment sce-
narios. In scenario 8, e.g. all patients default within
3 months. The percentages refer to the number of people
complying with the treatment for a certain period.
The beneﬁts of sub-optimal programmes are inversely
related to the level of defaulting. Compared to a scenario
without treatment, even scenario 6, with a high level of
defaulter rate (60% taking treatment for £ 4 months),
inducesinterestingbeneﬁts:70outof100TBpatientswould
be cured and 40 new pulmonary cases and 35 deaths would
be averted. Beneﬁts decrease considerably when the defaul-
ter rate increases beyond this level, as in scenarios 7 and 8.
Concerning the risk of creating single-drug resistance, no
scenario compares favourably with scenario 1, where the
risk of creating single-drug resistance is zero. In sub-
optimal settings, there is an increased risk of creating
single-drug resistance, with a predicted average of three
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is increasing constantly per treatment scenario and in
scenario 5, the MDR risk is nearly the double of the best
scenario (2.5& vs. 1.4&) while in scenario 7 the model
predicts a nearly 3-fold increase compared to scenario 1.
Economic consequences
Average marginal costs analysis of TB programmes shows
that treatment for Category I patients (new PTB + never
treatedbefore)costsonaverageUS$107,whileforCategory
IIpatients(PTB + relapsesandtreatmentfailures),thecostis
onaverageUS$176or64%moreexpensive(Dejongheet al.
1994).Thisisimportant,asthechronicexcreterscreatedina
sub-optimal programme will need a Category II re-treat-
ment, while the gain in future costs, because of the averted
new PTB(+) cases, will be calculated on a Category I
treatment. Table 4 shows this trade-off per defaulting
scenario.Thetrade-offiscalculated1 yearaftertheoutcome
ofeachscenario.Initialtreatmentcostsofthe100patientsof
each scenario are taken out for simpliﬁcation, as in scenario
0 most of the initial 100 untreated people also would still
need treatment after that. Discounting costs and savings for
the future did not show major changes.
Discussion
This paper suggests that when evaluating sub-optimal TB
programmes it is important to consider not only the public
health risks of the programme but also its beneﬁts.
Currently, few articles have stressed the importance of this
issue (Borgdorff et al. 2002).
If the health risks and beneﬁts of sub-optimal pro-
grammes are studied, it may be found that a threshold
0
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*
Figure 1 Risks and beneﬁts of sub-
optimal TB treatment programmes.
Table 4 Cost analysis per scenario for
one transmission cycle
Scenario
Cases needing
re-treatment/100
treatments
Cost for
re-treatments
(US$) (i)
New PTB(+)
averted/100
treatments (ii)
Gain in costs
of averted cases
(US$) (iii)
Net gain: ¼
(iii)i) (US$)
1 5 880 33 3531 2651
2 7 1232 32 3424 2192
3 16 2816 25 2675 141
4 17 2992 23 2461 )531
5 20 3520 21 2247 )1273
6 22 3872 20 2140 )1732
7 35 6160 9 963 )5197
8 42 7392 3 321 )7071
(i): One re-treatment costs US$176; (ii): each new pulmonary case has a 50% chance to be
PTB+. It is assumed that in the ﬁrst years post-conﬂict, only PTB(+) cases will be treated;
(iii): one treatment costs US$107.
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this model, this event occurs around scenario 6 (60%
follow at least 4-month treatment). If defaulting becomes
worse, the risks increase more signiﬁcantly and gradually
outweigh the beneﬁts. Such sub-optimal programmes
would lead to more adverse public health situations as
compared to offering no TB treatment programme at all.
We can therefore safely argue that a sub-optimal scenario
(between scenarios 5 and 6) in which 75% of the TB
patients receive at least 4 months of treatment is preferable
to a situation without a TB programme at all.
Of course the validity of the model and its assumptions
can be criticised. Changing certain assumptions and
parameter values certainly modiﬁes the beneﬁts and risks
predicted by the model. Increasing risks for MDR creation,
treatment failures and relapses weaken our assertion, while
lower risks conﬁrm it. As we have used the highest risk per
parameter found in the various sources and realistic
estimates for these scenarios, the model predictions of risks
and beneﬁts are unlikely to be overestimated. Moreover,
the probability of increased transmission of TB associated
with war situations was not taken into account, and the
number of new infections created by a TB patient was
calculated for one year of survival only, while the majority
of patients survive an average of 2 years. The number of
new cases and deaths averted thus tend to be underesti-
mated. The studies from which the model parameters were
obtained are clinical trial settings, where the situation is
obviously very different from ﬁeld conditions. However,
the lack of data under ﬁeld conditions makes them the only
source of information available for this study. The data are
considered appropriate for the following reasons: (i)
estimates of parameters are consistent between 13 studies;
(ii) parameters were deﬁned according to the internation-
ally accepted criteria; (iii) the results of these studies have
been used previously to deﬁne TB treatment guidelines;
(iv) some studies had a long follow-up period ranging from
19 to 60 months; and (v) where no data exist, realistic
estimates were proposed.
There are also other and longer treatment regimens (e.g.
2EHRZ/6EH) that might be considered. They would create
less MDR-TB and need less supervision. These regimens
have not been studied in this model because, in chronic
emergencies settings, most humanitarian agencies prefer to
adhere to the standard WHO regimen and complete
treatment as quickly as possible.
One important remark should be made on the effect of
HIVontheprevalenceandcureratesofTB.ThepresentHIV
epidemic dramatically increases TB incidence (e.g. Schulzer
1992). Mortality rates in HIV (+) patients are reported to
increasesigniﬁcantly:21%vs.6%insero-negative(HIV()))
patientsinNairobi(DeCock1994).TheresponseofHIV(+)
TB patients on a 6-month short course chemotherapy
regimen(SCC)isusuallysatisfactoryandcomparabletoHIV
()) patients (e.g. Perriens et al. 1995). It is also similar to
the assumptions used in the model. However, relapse rates
candifferbetweenHIV(+)andHIV())patients,asshownin
one study in Zaire (from 9 to 5.3%, respectively) (Perriens
et al. 1995). Other studies have not shown different relapse
rates, probably owing to the increased mortality of HIV (+)
patients (DeCock 1994; Sonnenberg 2001). Acquired
single-drug resistance among relapses seems frequent in
some studies (March et al. 1997; Centers for Disease
Control and Prevention 2002), while no difference is seen in
others (Perriens et al. 1995). Although the creation of
resistance depends mainly on the number of anti-TB drugs
used (Murray et al. 1990; WHO 1997), selective malab-
sorption may be at the origin of this higher acquired drug
resistance (Lutfey et al. 1996; Perlman et al. 1996).
Since the effect of HIV on TB treatment results is not
accounted for in the model, application of these results to
populations with a high HIV prevalence may not be
appropriate. A higher relapse rate will decrease beneﬁts
dramatically. A higher mortality among HIV (+) patients
may decrease this impact. Although some data suggest that
the creation of drug resistance is increased in full treatment
schemes, nothing is known about this in sub-optimal
programme settings. Lack of information makes it
impossible to take these inﬂuences into account in the
model. Decreased beneﬁts should also be challenged with
increased beneﬁts of a higher number of averted TB
patients due to the earlier TB treatment and a decreased
chance of re-infection (Sonnenberg 2001).
Looking at the trade-off between the extra costs of
treating relapses and failures and the savings in future
treatment costs, the short course chemotherapy (SCC) of
2SHRZ/4HR remains the most appropriate with maximal
beneﬁts. Scenario 3 remains also beneﬁcial with US$141
gained on future costs, whereas scenarios 5 and 6 cost
more (extra average cost of US$1500). If HIV sero-
prevalence is high, the gains and costs will again depend on
the balance between a higher relapse rate, an increased
mortality and a higher number of averted cases. Treatment
of MDR-TB cases has not been accounted for, as their
number is considered as minimal (average of 3&) and their
treatment impossible in these settings.
These ﬁndings should not prevent us from considering
the above-mentioned sub-optimal scenarios as beneﬁcial
where the majority (i.e. 75%) of patients receive at least
4 months of treatment. Costs will indeed increase with the
number of relapses and treatment failures. The extra costs
of a treatment scenario between scenarios 5 and 6 can still
be accepted, when taking into account the social cost of
prolonged human suffering, such as premature deaths,
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the absence of a treatment programme.
It is importanttostress that this is only a partialeconomic
analysis. One can indeed argue that a 25% cure rate will
happen withouttreatmentandthatthis shouldbe takeninto
account. Others will argue that at least four transmission
cycles should be studied in a cost-effectiveness study of
tuberculosis (Murray et al. 1993; Dejonghe et al. 1994). It
should be remembered that other cost-effectiveness studies
have compared a 6-month SCC to alternative treatment
protocols, whereas the originality of this discussion is in its
application to extreme circumstances, where sub-optimal
programmes are compared to a scenario without treatment.
Moreover, cost-effectiveness is rarely an objective for
humanitarian agencies in complex emergencies, when
human life and survival are at stake. These agencies aim to
ease human suffering and do not delay actions simply
because they would appear to be cheaper in a more peaceful
environment. If agencies do not start TB treatment pro-
grammesinsomesettings,theydosowiththeprimeconcern
ofnotharmingpatients.Themodel’soutcomesshouldthus
reassure these agencies that treatment programmes, where
75%ofthepatientscanfollowatleast4 monthsmulti-drug-
treatment, could still be considered as more efﬁcacious as
compared to the absence of a TB treatment programme. In
addition, these programmes do not represent a major public
health threat and the costs are not unacceptably high.
In this article, we conclude that programmes should
always aim for a 6-month SCC with an 85% cure rate,
according to the international guidelines. However, in
complex emergencies 4 months of multi-drug-treatment
(2SHRZ/2HR) could represent a minimum, which should
be reached by the majority (i.e. 75%) of patients. This
article shows that the defaulting rate remains an important
indicator for the quality of a programme. By looking at the
time of defaulting the public health implications of the TB
programme can be assessed. The proportion of patients
following at least 4 months of treatment can therefore be
considered as an important indicator when evaluating the
public health harm and beneﬁts of a TB programme. This
indicator should be consolidated with the early treatment
results (smear conversion by 2–3 months), as recommen-
ded by WHO and UNHCR (1997) to conﬁrm the quality of
the early response to treatment.
Humanitarian agencies not only need to follow the
international guidelines but also balance the risks and
beneﬁts of TB programmes in complex emergencies. No
programme may mean that patients seek treatment from
unqualiﬁed practitioners. In contrast, a sub-optimal pro-
gramme where patients receive correct treatment for at
least 4 months may have a much greater and more positive
public health impact.
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